22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The fifth of a six-part series examining six specific and evolving rights plan provisions. As discu...
Read More >
Speed read - New merger control guidelines in Indonesia provide that asset acquisitions are now tra...
Read More >
As the time taken to secure merger control clearances for global transactions lengthens, the parties...
Read More >
The hashtag “MeToo” went viral in October of 2017. In the two years since then, the movement has h...
Read More >
When you think about personal injury lawyers, is the first thing that comes to mind “what great adv...
Read More >
Construction project impacts from the COVID-19 pandemic are far-reaching and continuing to evolve. W...
Read More >